GC Therapeutics key facts
- Developer of a genome-wide cell programming platform designed to convert patient-derived stem cells into multiple cell types.
- GC Therapeutics’s last known valuation is $135.0M.
- It has raised $74.7M; the latest was Later Stage VC ($65.0M) in Sep 2024.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Global Brain, Gaingels, Calm Ventures — 14 tracked in total.
- Status: Privately Held (backing).
Who backs GC Therapeutics
14+- ·The complete investor list: 14 names
- ·Watch GC Therapeutics: the Monday email on marks, rounds and moves
GC Therapeutics funding rounds
No funding rounds for GC Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
GC Therapeutics valuation
GC Therapeutics's last known valuation is $135 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
GC Therapeutics investors
14 investors are on record for GC Therapeutics, including Alumni Ventures, Andreessen Horowitz, Global Brain and Gaingels. By type, the record holds 8 venture capital firms and 1 asset manager.
About GC Therapeutics
Developer of a genome-wide cell programming platform designed to convert patient-derived stem cells into multiple cell types. The company integrates synthetic biology, artificial intelligence, and proprietary differentiation technology to create cell therapies with streamlined manufacturing and improved quality, enabling healthcare professionals to access advanced cell therapy options for patient care.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2019
- Employees
- 42
- Website
- gc-tx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
GC Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.